What it is
A synthetic small molecule of the benzylpiperazine-aminopyridine class, studied historically as an investigational antidepressant.
How it works
Proposed in preclinical studies to stimulate hippocampal neurogenesis and increase hippocampal volume in rodent models, though the exact molecular target is not fully characterized.
Where it's used
Investigated in Phase 1 and 2 clinical trials for major depressive disorder; did not achieve regulatory approval. No longer in active development.
Regulatory status
Not FDA-approved; investigational compound, development discontinued.
Tracking it
NSI-189 is oral, which makes consistency the whole game — a simple daily check-off with a reminder beats memory every time. with a half-life of about 20 hours, a dose log also lets a tracker model the relative amount still in your system between doses.
Source
Public reference
Last reviewed 2026-06-11